PD21-09 daily tadalafil therapy: a NEW treatment option for peyronie’s disease?
Abstract
INTRODUCTION AND OBJECTIVES: It has been speculated that phosphodiesterase type 5 inhibitors may have an effect on Peyronie's disease (PD) by inhibiting tissue remodeling after acute injury and decreasing the oxidative stress responsible for inflammation and fibrosis. This study evaluated the efficacy of tadalafil in patients with PD. METHODS: 66 patients diagnosed with PD were divided into three groups. Group 1 (20 patients) were treated with an intralesional injection of verapamil (IVI); group 2 (23 patients) were treated with 5 mg tadalafil once daily, and group 3 (23 patients) were administered IVI and 5 mg tadalafil once daily for 12 weeks. The size of plaques, degree of penile curvature, pain on erection, and severity of erectile dysfunction (ED) were evaluated at baseline and 12 weeks into the study. RESULTS: The mean ages of the three groups were 53.2 ± 7.7, 56.1 ± 8.1, and 55.3 ± 7.1 years, respectively. No differences in age, erectile function, or duration and characteristics of PD were observed among the groups at baseline. Pain resolution was achieved in 55%, 70%, and 78.3% of patients in the groups after 12 weeks (p < 0.01). The changes in the mean degree of curvature were -4.6 ± 3.2, -6.2 ± 4.4, and -7.2 ± 4.5 in the groups (p < 0.01). The changes in mean plaque size were 0.2 ± 0.1, 0.2 ± 0.2, and 0.3 ± 0.2 cm2 in the groups (p < 0.01). Groups 2 and 3 showed a greater increase in the International Index of Erectile Function-erectile function domain score (0.4 ±…
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.